An association between anti-platelet drug use and reduced cancer prevalence in diabetic patients: Results from the Vermont Diabetes Information System Study

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Holmes, Chris E ^a   Ramos Nino, Maria E ^a   Littenberg, Benjamin ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CLOPIDOGREL; HEMOGLOBIN A1C; TICLOPIDINE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; CANCER EPIDEMIOLOGY; CANCER RISK; COMORBIDITY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE ASSOCIATION; FEMALE; HUMAN; INFORMATION SYSTEM; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PREVALENCE; PRIMARY MEDICAL CARE; RISK REDUCTION; SELF REPORT; SEX DIFFERENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECISION SUPPORT SYSTEM; INCIDENCE; MIDDLE AGED; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; RISK; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; TIME; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; DECISION SUPPORT SYSTEMS, CLINICAL; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASMS; NEW YORK; ODDS RATIO; PLATELET AGGREGATION INHIBITORS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; VERMONT; YOUNG ADULT;

EID: 77953403443     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-289     Document Type: Article

References (25)

1. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 2005, 97(22):1679-1687. 10.1093/jnci/dji375, 16288121.
2. Friberg E, Mantzoros CS, Wolk A. Diabetes and risk of endometrial cancer: a population-based prospective cohort study. Cancer Epidemiol Biomarkers Prev 2007, 16(2):276-280. 10.1158/1055-9965.EPI-06-0751, 17301260.
3. Wideroff L, Gridley G, Mellemkjaer L, Chow WH, Linet M, Keehn S, Borch-Johnsen K, Olsen JH. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997, 89(18):1360-1365. 10.1093/jnci/89.18.1360, 9308706.
4. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 2004, 159(12):1160-1167. 10.1093/aje/kwh161, 15191933.
5. Giovannucci E. Diet, body weight, and colorectal cancer: a summary of the epidemiologic evidence. Journal of women's health (2002) 2003, 12(2):173-182. 10.1089/154099903321576574, 12737716.
6. Giovannucci E. Nutrition, insulin, insulin-like growth factors and cancer. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 2003, 35(11-12):694-704.
7. Sobel BE, Schneider DJ. Platelet function, coagulopathy, and impaired fibrinolysis in diabetes. Cardiol Clin 2004, 22(4):511-526. 10.1016/j.ccl.2004.06.009, 15501620.
8. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 1989, 321(3):129-135.
9. Nash GF, Turner LF, Scully MF, Kakkar AK. Platelets and cancer. Lancet Oncol 2002, 3(7):425-430. 10.1016/S1470-2045(02)00789-1, 12142172.
10. Sierko E, Wojtukiewicz MZ. Platelets and angiogenesis in malignancy. Semin Thromb Hemost 2004, 30(1):95-108. 10.1055/s-2004-822974, 15034801.
11. Jurasz P, North S, Venner P, Radomski MW. Matrix metalloproteinase-2 contributes to increased platelet reactivity in patients with metastatic prostate cancer: a preliminary study. Thromb Res 2003, 112(1-2):59-64. 10.1016/j.thromres.2003.10.012, 15013275.
12. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002, 94(4):252-266.
13. Gasic GJ, Gasic TB, Stewart CC. Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci USA 1968, 61(1):46-52. 10.1073/pnas.61.1.46, 285903, 5246932.
14. Nierodzik ML, Klepfish A, Karpatkin S. Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo. Thromb Haemost 1995, 74(1):282-290.
15. MacLean CD, Littenberg B, Gagnon M, Reardon M, Turner PD, Jordan C. The Vermont Diabetes Information System (VDIS): study design and subject recruitment for a cluster randomized trial of a decision support system in a regional sample of primary care practices. Clin Trials 2004, 1(6):532-544. 10.1191/1740774504cn051oa, 2518939, 16279294.
16. Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN. The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum 2003, 49(2):156-163. 10.1002/art.10993, 12687505.
17. Miller SR, Littenberg B, MacLean CD. Prevalence of antiplatelet therapy in patients with diabetes. Cardiovasc Diabetol 2005, 4:18. 10.1186/1475-2840-4-18, 1318485, 16321162.
18. Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ, Chaussade S, Baron JA. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst 2009, 101(4):256-266. 10.1093/jnci/djn485, 19211452.
19. Harris RE, Chlebowski RT, Jackson RD, Frid DJ, Ascenseo JL, Anderson G, Loar A, Rodabough RJ, White E, McTiernan A. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res 2003, 63(18):6096-6101.
20. Takkouche B, Regueira-Mendez C, Etminan M. Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J Natl Cancer Inst 2008, 100(20):1439-1447. 10.1093/jnci/djn324, 18840819.
21. Eliassen AH, Chen WY, Spiegelman D, Willett WC, Hunter DJ, Hankinson SE. Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and risk of breast cancer among premenopausal women in the Nurses' Health Study II. Arch Intern Med 2009, 169(2):115-121. discussion 121, 10.1001/archinternmed.2008.537, 2632770, 19171806.
22. Becker DM, Segal J, Vaidya D, Yanek LR, Herrera-Galeano JE, Bray PF, Moy TF, Becker LC, Faraday N. Sex differences in platelet reactivity and response to low-dose aspirin therapy. Jama 2006, 295(12):1420-1427. 10.1001/jama.295.12.1420, 16551714.
23. Jacobs EJ, Rodriguez C, Mondul AM, Connell CJ, Henley SJ, Calle EE, Thun MJ. A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J Natl Cancer Inst 2005, 97(13):975-980. 10.1093/jnci/dji173, 15998950.
24. Kohga S, Kinjo M, Tanaka K, Ogawa H, Ishihara M, Tanaka N. Effects of 5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrochloride (Ticlopidine), a platelet aggregation inhibitor, on blood-borne metastasis. Cancer Res 1981, 41(11 Pt 1):4710-4714.
25. Razmara M, Hjemdahl P, Ostenson CG, Li N. Platelet hyperprocoagulant activity in Type 2 diabetes mellitus: attenuation by glycoprotein IIb/IIIa inhibition. J Thromb Haemost 2008, 6(12):2186-2192. 10.1111/j.1538-7836.2008.03185.x, 18983513.